Efficacy of endoluminal gastroplication in Japanese patients with proton pump inhibitor-resistant, non-erosive esophagitis

Figure 1 Rate of discontinuation or reduction by more than 50% of proton pump inhibitor use.

Figure 2 Relationship with the plication number and symptom or proton pump inhibitor use. A: Relationship between the number of plications and the score of the frequency scale for symptoms of gastro-esophageal reflux disease. There is no significant difference between the two groups (remaining pliccations 0 vs one or more) after 3 or 12 mo after endoluminal gastroplication (ELGP); B: Relationship between the number of plications and the rate of proton pump inhibitor (PPI) use. The group with one or more remaining plications shows a tendency to reduced PPI use 3 mo after ELGP (P = 0.07). However, there is no significant difference between the groups after 12 mo of ELGP.

Figure 3 Symptom sensitivity index transition at baseline and 3 mo after endoluminal gastroplication.